Improving the understanding of originator and biosimilar biologics among healthcare providers in Saudi Arabia

The loss of patentability of many originator biologics has led to the rapid introduction of biosimilar agents. The anticipated economic benefit of introducing such agent has been accompanied by vagueness surrounding their biotechnology, approval requirements, positioning in treatment paradigms and p...

Descripción completa

Detalles Bibliográficos
Autores principales: Omair, Mohammed A., Alhawassi, Tariq, Alwaihibi, Munira, Aldrees, Ghada, Mosli, Mahmoud, Asser, Wesam M., Alharaibi, Maryam A., Alotaibi, Atheer T., Bintaleb, Doaa A., Alharbi, Najah K., Alotaibi, Ahmed Z., Alshammari, Wajed A., Alanazi, Nouf, Asiri, Ali M., Almadany, Rana, Al Rayes, Hanan, Al-Thunian, Turki, Alotaibi, Moureq, Al Jazaeri, Abdulrazaq
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783213/
https://www.ncbi.nlm.nih.gov/pubmed/33424270
http://dx.doi.org/10.1016/j.jsps.2020.11.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783213/
https://www.ncbi.nlm.nih.gov/pubmed/33424270
http://dx.doi.org/10.1016/j.jsps.2020.11.008

Ejemplares similares